3 Industrial Stocks Under $50 to Buy in October

Amentum booked over $1B in classified defense awards and reported $135M in Q3 free cash flow, but lowered FY2026 revenue guidance to $13.8B–$13.95B and carries $3.9B in gross debt. Intuitive Machines’ Q2 2026 revenue more than quadrupled year over year to $206M, though it posted a $62.8M GAAP loss and negative $145.8M first-half free cash flow. ZIM raised FY2026 adjusted EBITDA guidance to $2.7B–$3B, while its proposed Hapag-Lloyd deal—which could deliver $35 per share at close—faces regulatory uncertainty in Israel.

Analysis

The key distinction is cash conversion, not headline backlog. For Amentum, awards can support visibility but do not remove the gap between total and funded backlog: revenue timing and cash collection remain exposed to appropriations, task-order release and execution. The more useful near-term signal is whether free cash flow stays positive and is directed to debt reduction while revenue guidance is lower. If not, the backlog may support the narrative without improving equity value.

Intuitive Machines has the most convex upside, but acquisition-inflated backlog and rapid revenue growth can obscure the economics of delivery. Persistent cash burn raises the chance that shareholders, rather than operating cash flow, fund the growth path; fixed-price execution or integration slippage could therefore hurt more than a modest revenue miss. The 18-spacecraft award is not, by itself, evidence of attractive contract margins.

ZIM is a two-factor position: a regulatory-dependent transaction plus a highly cyclical freight business. The proposed $35 consideration is not a floor until approvals and closing conditions are sufficiently certain. A failed deal would return investors to standalone earnings just as shipping-rate and capacity shifts can overwhelm a strong current EBITDA outlook. Hapag-Lloyd also faces approval and execution risk; a blocked transaction could remove prospective consolidation benefits without changing the industry's underlying capacity cycle.

Near term, deal-process headlines and freight rates should dominate ZIM; over 1–3 months, watch Amentum cash conversion and ZIM regulatory progress; over 6–18 months, funded backlog conversion, LUNR dilution/contract profitability, and shipping capacity are the decisive tests. The contrarian point: backlog growth is not equivalent to funded, profitable revenue, and a low nominal share price says nothing about valuation.

Key Decisions for Investors

• AMTM: Prefer evidence over award headlines. Consider staged exposure only if subsequent reports show positive free cash flow alongside net-debt reduction; reassess on another guidance cut, weakening cash conversion, or no progress in funded-backlog conversion.
• LUNR: Keep exposure small or wait for evidence that acquired and awarded work is converting into improving operating cash flow. Treat continued large cash burn, a financing/dilution event, or weak contract economics as thesis-falsifying; do not value the 18-spacecraft award as profitable revenue without margin disclosure.
• ZIM: Avoid treating the proposed $35-per-share deal value as downside protection. A deal-arbitrage position is only worth considering after a viable regulatory filing and clearer approval path; size for a failed deal and weaker freight rates, and monitor Israeli regulatory milestones and spot/container-rate indicators.
• No clean pair trade is established by these facts alone: AMTM, LUNR and ZIM have materially different operating drivers. Revisit relative value after current prices, deal terms/conditions, and the companies’ latest cash-flow and debt data are verified.